Celgene Teams Up With Agios In Long-Term Cancer Metabolism Pact
This article was originally published in Start Up
Executive Summary
The April 15 deal between Agios Pharmaceuticals Inc., a start-up barely two years old working in a novel area of cancer research, and Celgene Corp. is noteworthy for a number of reasons, among them its sheer size: the $130 million up-front payment associated with the deal is the largest year-to-date for a pharmaceutical alliance for which metrics have been disclosed, and is particularly hefty for a start-up that has yet to put a molecule in the clinic.
You may also be interested in...
Financings Of The Fortnight Looks For A Strong IPO Year To Pick Up Further In Second Half
Looking ahead to Start-Up’s third annual life science venture survey, optimism seems on the upswing and FOTF looks for an even stronger pace of IPOs in the second half of 2013. Plus news on financings by Agios, Merrimack, OncoMed and Alcresta.
Agios Opens Doors To Other Investors, Expands Into Genetic Disorders
Agios brings in a $78 million in financing from both previous venture investors and new public investor funds, as it embarks on research of rare diseases caused by an inborn error of metabolism.